NCT03718884View on ClinicalTrials.gov

A Study of Mirikizumab in Participants With Plaque Psoriasis

PHASE1CompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

October 23, 2018

Primary Completion Date

October 28, 2019

Study Completion Date

October 28, 2019

Conditions
Psoriasis
Interventions
DRUG

Drug Cocktail

Drug cocktail consists of caffeine, warfarin plus vitamin K, omeprazole, dextromethorphan, and midazolam, administered orally

DRUG

Mirikizumab

Administered SC

Trial Locations (3)

27265

High Point Clinical Trials Center, High Point

32720

Avail Clinical Research LLC, DeLand

92801

Anaheim Clinical Trials, LLC, Anaheim

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT03718884 - A Study of Mirikizumab in Participants With Plaque Psoriasis | Biotech Hunter | Biotech Hunter